Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Lymphoma

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

Br J Haematol

Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S, ATL working groups of the Japanese Society for Transplantation and Cellular Therapy

doi: 10.1111/bjh.70631

Multiple Myeloma (MM)

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Blood Cancer J

Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ

doi: 10.1038/s41408-026-01469-z

Leukemia

Prognostic factors and survival outcomes of first CNS relapse in childhood acute lymphoblastic leukemia: results from the ALL-IC REL 2016 study

Leuk Lymphoma

Hazar V, Makiya M, Yalçın K, Cadiu JT, Manni F, Reyes Barragan A, Polychronopoulou S, Colita A, Avramova B, Kavcic M, Ampatzidou M, Radu LE, Hristova T, Prelog T, Höbör B, Farah R, Jazbec J, Erdelyi DJ

doi: 10.1080/10428194.2025.2598861

Lymphoma

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

Leuk Lymphoma

Kim DH, Cha S, Koh Y, Byun JM

doi: 10.1080/10428194.2026.2638438

Lymphoma

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns

Haematologica

Stuver R, Moore ZR, Barta SK, Bhansali RS, Choa R, Epstein-Peterson ZD, Ganesan N, Ghione P, Jain S, Jacobsen E, Johnson WT, Lukowski JD, Lunning M, McCabe S, Merrill M, Moskowitz AJ, Singh S, Taranto E, Yahalom J, Savage KJ, Imber BS, Horwitz SM

doi: 10.3324/haematol.2026.300853

Lymphoma

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Lancet Haematol

Spanjaart AM, Bakker M, de Vries R, Hutten BA, van Nieuwenhuijzen N, Minnema MC, Kuipers MT, Kersten MJ

doi: 10.1016/S2352-3026(26)00045-1

Lymphoma

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

N Engl J Med

Ruella M, Paruzzo L, Chong ER, Chong EA, Landsburg DJ, Nasta SD, Devi P, Michener P, Stella F, Carturan A, Napier EB, Van Deerlin VM, Porazzi P, Levine BL, Frey N, Porter DL, Fraietta JA, Svoboda J, June CH, Schuster SJ

doi: 10.1056/NEJMoa2518035

Lymphoma

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

Br J Haematol

Hossain NM, Ahn KW, Patel J, Lian Q, Abid B, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF

doi: 10.1111/bjh.70020

EHA/ICML 2025

Lymphoma

Related content

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Prognostic factors and survival outcomes of first CNS relapse in childhood acute lymphoblastic leukemia: results from the ALL-IC REL 2016 study

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

Expanding the Curative Potential of CAR T-Cell Therapy